Barclays’s Genocea Biosciences, Inc. GNCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-3
| Closed | – | – | 5381 |
|
|
2022
Q2 | $0 | Buy |
+3
| New | +$1 | ﹤0.01% | 5531 |
|
|
2021
Q2 | – | Sell |
-1,763
| Closed | -$5K | – | 5217 |
|
|
2021
Q1 | $5K | Buy |
+1,763
| New | +$5.22K | ﹤0.01% | 4492 |
|
|
2020
Q3 | – | Sell |
-56
| Closed | – | – | 5863 |
|
|
2020
Q2 | $0 | Buy |
+56
| New | +$129 | ﹤0.01% | 6592 |
|
|
2019
Q3 | – | Sell |
-14,324
| Closed | -$58K | – | 7485 |
|
|
2019
Q2 | $58K | Buy |
+14,324
| New | +$74.7K | ﹤0.01% | 6030 |
|
|
2018
Q3 | – | Sell |
-543
| Closed | -$4K | – | 7613 |
|
|
2018
Q2 | $4K | Sell |
543
-1,591
| -75% | -$11.9K | ﹤0.01% | 6768 |
|
|
2018
Q1 | $18K | Buy |
2,134
+1,193
| +127% | +$9.91K | ﹤0.01% | 6481 |
|
|
2017
Q4 | $8K | Buy |
941
+858
| +1,034% | +$8.63K | ﹤0.01% | 6585 |
|
|
2017
Q3 | $1K | Sell |
83
-838
| -91% | -$31.8K | ﹤0.01% | 6804 |
|
|
2017
Q2 | $38K | Sell |
921
-1,204
| -57% | -$58K | ﹤0.01% | 5504 |
|
|
2017
Q1 | $104K | Buy |
+2,125
| New | +$83K | ﹤0.01% | 4855 |
|
|
2016
Q3 | – | Sell |
-264
| Closed | -$9K | – | 6919 |
|
|
2016
Q2 | $9K | Buy |
+264
| New | +$9.68K | ﹤0.01% | 5595 |
|
|
2015
Q4 | – | Sell |
-14
| Closed | -$1K | – | 6906 |
|
|
2015
Q3 | $1K | Sell |
14
-30
| -68% | -$2.98K | ﹤0.01% | 6696 |
|
|
2015
Q2 | $4K | Buy |
44
+27
| +159% | +$2.51K | ﹤0.01% | 6611 |
|
|
2015
Q1 | $1K | Sell |
17
-23
| -58% | -$1.62K | ﹤0.01% | 7010 |
|
|
2014
Q4 | $2K | Buy |
40
+24
| +150% | +$1.64K | ﹤0.01% | 7143 |
|
|
2014
Q3 | $1K | Buy |
16
+8
| +100% | +$876 | ﹤0.01% | 7566 |
|
|
2014
Q2 | $1K | Sell |
8
-5
| -38% | -$759 | ﹤0.01% | 7544 |
|
|
2014
Q1 | $2K | Buy |
+13
| New | +$1.59K | ﹤0.01% | 7424 |
|
Other funds holding GNCA
Barclays's GNCA Position: Q3 2022 in Review
Barclays sold out of Genocea Biosciences, Inc. (GNCA) in Q3 2022, closing a stake of 3 shares.
Barclays first reported a position in GNCA in Q1 2014 and held it in 18 quarters. The position peaked at $104K in Q1 2017. 1 fund tracked by Wall St. Rank holds GNCA as of Q3 2022.
- Barclays reported no remaining Genocea Biosciences, Inc. position as of Q3 2022 after selling out during the quarter.
- Barclays sold 3 Genocea Biosciences, Inc. shares in Q3 2022.
- Barclays first reported a position in Genocea Biosciences, Inc. in Q1 2014 and held it in 18 quarters.
- Barclays's Genocea Biosciences, Inc. position peaked at $104K in Q1 2017.
- 1 fund tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q3 2022.
Based on Barclays's 13F filing for Q3 2022, filed 3 Nov 2022.